Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Chan, S. L. [1 ]
Miksad, R. [2 ]
Cicin, I. [3 ]
Chen, Y. [4 ]
Klumpen, H. J. [5 ]
Kim, S. [6 ]
Lin, Z. Z. [7 ]
Youkstetter, J. [8 ]
Sen, S. [8 ]
Cheng, A-L. [9 ]
El-Khoueiry, A. B. [10 ]
Meyer, T. [11 ]
Kelley, R. K. [12 ]
Abou-Alfa, G. K. [13 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Oncol South China, Hong Kong, Peoples R China
[2] Beth Israel Deaconess Med Ctr, Res Oncol, New York, NY USA
[3] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[4] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[5] AMC, Med Oncol, Amsterdam, Netherlands
[6] Ctr Hosp Reg Univ Besancon, Med Oncol, Besancon, France
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Exelixis Inc, Dept Oncol, Alameda, CA USA
[9] Natl Taiwan Univ Hosp, Canc Ctr, Taipei, Taiwan
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[11] UCL, Dept Oncol, London, England
[12] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[13] Mem Sloan Kettering Canc Ctr, Dept Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
127P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
    Kelley, Robin Kate
    Meyer, Tim
    Rimassa, Lorenza
    Merle, Philippe
    Park, Joong-Won
    Yau, Thomas
    Chan, Stephen L.
    Blanc, Jean-Frederic
    Tam, Vincent C.
    Tran, Albert
    Dadduzio, Vincenzo
    Markby, David W.
    Kaldate, Rajesh
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Abou-Alfa, Ghassan K.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4795 - 4804
  • [32] Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy
    Ye, Linsen
    Liang, Rongpu
    Zhang, Jiebin
    Chen, Chaojin
    Chen, Xiaolong
    Zhang, Yi
    Wang, Guoying
    Yang, Yang
    Chen, Guihua
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (16)
  • [33] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced Hepatocellular Carcinoma (HCC)
    Waidmann, O.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Harris, W. P.
    Nemunaitis, J.
    Olteanu, S.
    Sarker, D.
    Tan, B. R.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L
    El-Khoueiry, A. B.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 284
  • [34] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Merle, P.
    Rimassa, L.
    Ryoo, B.
    Cicin, I.
    Harris, W.
    Banu, E.
    Sarker, D.
    Tan, B.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 104 - 104
  • [35] HIV-associated hepatocellular carcinoma: validation of the albumin-bilirubin (ALBI) grade as a prognostic indicator in 387 patients
    Pinato, D.
    Pria, A. D.
    Aravind, P.
    Froeling, F.
    Nelson, M.
    Bower, M.
    Sharma, R.
    Merli, M.
    Brau, N.
    HIV MEDICINE, 2017, 18 : 39 - 39
  • [36] Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation
    Kao, Wei-Yu
    Su, Chien-Wei
    Chiou, Yi-You
    Chiu, Nai-Chi
    Liu, Chien-An
    Fang, Kuan-Chieh
    Huo, Teh-la
    Huang, Yi-Hsiang
    Chang, Chun-Chao
    Hou, Ming-Chih
    Lin, Han-Chieh
    Wu, Jaw-Ching
    RADIOLOGY, 2017, 285 (02) : 670 - 680
  • [37] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Outcomes By Baseline Alpha-Fetoprotein (AFP) Levels in the Phase 3 Celestial Trial of Cabozantinib (C) Versus Placebo (P) in Previously Treated Advanced Hepatocellular Carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony B.
    Meyer, Timothy
    Rimassa, Lorenza
    Merle, Philippe
    Chan, Stephen L.
    Tran, Albert
    Parnis, Francis
    Tam, Vincent C.
    Cattan, Stephane
    Markby, David W.
    Clary, Douglas O.
    Cheng, Ann-Lii
    Kelley, Robin Kate
    HEPATOLOGY, 2018, 68 : 533A - 534A
  • [39] Outcomes in patients who had received sorafenib as the only prior systemic therapy in the Phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Strasser, S. I.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 21 - 22
  • [40] Albumin-bilirubin grade as a predictor of survival in hepatocellular carcinoma patients with thrombocytopenia
    Man, Zhong-Ran
    Gong, Xuan-Kun
    Qu, Kang-Lin
    Pang, Qing
    Wu, Bin-Quan
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (05) : 1763 - 1772
12345